K

Kiniksa Pharmaceuticals Ltd
D

KNSA

38.595
USD
-2.45
(-5.96%)
مغلق
حجم التداول
20,430
الربح لكل سهم
1
العائد الربحي
-
P/E
86
حجم السوق
2,925,337,319
أصول ذات صلة المقالات

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.